Home > Dermatology > “Encouraging” data on ipilimumab plus anti-PD-1 in metastatic melanoma

“Encouraging” data on ipilimumab plus anti-PD-1 in metastatic melanoma

Journal
Lancet Oncology
Reuters Health - 31/05/2021 - For patients with advanced melanoma resistant to anti-PD-(L)1 monotherapy, combining the CTLA-4 inhibitor ipilimumab with an anti-PD-1 agent "should be favored" over ipilimumab alone as second-line immunotherapy, researchers say. Anti-PD-1 therapy induces long-term disease control in about 30% of patients with metastatic melanoma. However, two-thirds of patients are resistant to anti-PD-1 therapy and will require further treatment, Dr. Ines Pires da Silva of the University of Sydney, Australia, and colleagues note in The Lancet Oncology. The researchers reviewed the outcomes with ipilimumab alone or with the anti-PD-1 drugs pembrolizumab or nivolumab (combination immune-checkpoint inhibitor immunotherapy) in 355 patients with metastatic melanoma resistant to anti-PD-(L)1 therapy. Patients who received combination therapy were younger than those who received ipilimumab monotherapy (median age 61 vs. 67 years), had a better Eastern...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on